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Duchenne and Becker muscular dystrophy (DMD and BMD) are X-linked diseases resulting from a defect in the dystrophin
gene located on Xp21. DMD is the most frequent neuromuscular disease in humans (1/3500 male newborn). Deletions in the
dystrophin gene represent 65% of mutations in DMD/BMD patients. We have analyzed DNA from 72 Moroccan patients with
DMD/BMD using the multiplex polymerase chain reaction (PCR) to screen for exon deletions within the dystrophin gene,
and to estimate the frequency of these abnormalities. We found dystrophin gene deletions in 37 cases. Therefore the frequency
in Moroccan DMD/BMD patients is about 51.3%. All deletions were clustered in the two known hot-spots regions, and in
81% of cases deletions were detected in the region from exon 43 to exon 52. These ﬁndings are comparable to those reported
in other studies. It is important to note that in our population, we can ﬁrst search for deletions of DMD gene in the most
frequently deleted exons determined by this study. This may facilitate the molecular diagnosis of DMD and BMD in our country.
INTRODUCTION
Duchenne and Becker muscular dystrophy (DMD and
BMD) represent the most common genetic neuromuscular
disease of childhood. DMD is relatively frequent, with an in-
cidence of 1 in 3500 male live births. In a typical aﬀected
male, clinical symptoms arise around the age of 3 years with
progressive muscle weakness. The patient is nonambulatory
by the age of 9 or 10 years and usually dies by 20 years of age,
following cardiac or respiratory complications. On the other
hand, Becker muscular dystrophy (BMD) is a milder form
characterized by a slower disease course, with death gener-
ally occurring in the third or fourth decade.
DMD and BMD are characterized by an X-linked pattern
of inheritance, thus aﬀecting mainly males. However, they
have also been occasionally reported in females, in cases of
skewed X-inactivation or X chromosome abnormalities [1].
DMD and BMD are allelic variants, produced by a defect
in a large gene localized on the short arm of the X chromo-
some (Xp21). This gene was sequenced by Koenig et al [2],
spans approximately 2.4megabases and consists of at least 79
exons [3,4].Itstranscriptisa14kilobase(kb)mRNAencod-
ing the dystrophin protein, a rod-shaped cytoskeletal protein
of approximately 427kda molecular weight, localized to the
sarcolemma inside the skeletal muscle ﬁbres [5, 6, 7]. West-
ern blot analysis generally shows that the dystrophin protein
is absent or drastically reduced in the muscles of DMD pa-
tients, while it is present but reduced in amount and/or in
size in BMD patients [8, 9].
In approximately 65% of DMD and BMD patients, dele-
tions in the dystrophin gene have been identiﬁed [2, 10, 11]
without correlation between the size of the deletion and the
severity of the disorder. In DMD, deletions that result in dis-
ruption of the translational reading frame prevent the pro-
ductionofastableprotein,whileinBMD,deletionsmaintain
the proper reading frame which results in abnormal but sta-
ble and partially functional proteins [9]. Partial duplications
are responsible for 6 to 7% of DMD gene mutations [12].
Duchenne cases without deletions, representing one third of
allcases[14],areprobablytheresultofpointmutations[15].
The screening for DMD/BMD gene deletions can be car-
ried out using Southern blotting with cDNA probes or by
PCR.Thelatterapproachallowsthedetectionof98%ofdele-
tions in the DMD gene [13] (64.7% of patients).
In this paper, we report the ﬁrst DNA analysis of unre-
lated Moroccan DMD/BMD patients by multiplex PCR. Be-
cause of its simplicity, rapidity, reduced cost, and its non-
radioactive approach, this technique is very practical for the
molecular diagnosis of this disorder in our country.
MATERIALS AND METHODS
Patients
Allthepatients werereferredforDNAanalysisfromneu-
rological and pediatric departments in Morocco. In some
patients, dystrophin analysis by Western blot was also per-
formed.
The diagnosis of DMD or BMD was based on clinical
ﬁndings, Electromyography (EMG), the transmission of the
pattern as an X-linked trait, an elevated serum creatine ki-
nase activity, and dystrophin analysis when parental consent2:3 (2002) Analysis of Dystrophin Gene Deletions by Multiplex PCR in Moroccan Patients 159
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Figure 1. Analysis of dystrophin gene by multiplex PCR. I: patient with
deletion of exon 45, II: patient with deletion of exon 48, and III: normal
control. The numbers at the right indicate the ampliﬁed exons.
for a muscle biopsy was obtained. The mean age at referral
w a s1 0y e a r s ;t h ea g er a n g ew a sb e t w e e n4a n d3 2y e a r s .
MultiplexPCR
DNA was isolated from peripheral blood leukocytes us-
ing standard phenol/chloroform procedures. Multiplex DNA
ampliﬁcations of the dystrophin gene were carried out ac-
cording to Chamberlain et al [16]a n dB e g g se ta l[ 13], using
two multiplex PCR assays allowing the ampliﬁcation of 9 ex-
ons each: the Chamberlain reaction using primers for exons
45, 48, 19, 17, 51, 8, 12, 44, 4, and the Beggs reaction per-
formed with primers for the promoter and exons 3, 43, 50,
13, 6, 47, 60, and 52 (Figure 1). In some cases, the Chamber-
lain reaction modiﬁed by Beggs et al [17] allowed ampliﬁca-
tion of exon 46 plus the original set (because at the onset of
this study, the primers of exon 46 were not available). The
PCR products were separated on 2% nusieve +1% agarose
minigels and the bands visualized by staining with ethidium
bromide.
RESULTS AND DISCUSSION
We have analysed, by multiplex PCR, 72 DNA samples
from unrelated patients diagnosed with Becker or Duchenne
muscular dystrophy cases based on clinical and electrophysi-
ological ﬁndings. In 31 cases, the diagnosis was conﬁrmed by
dystrophin analysis after Western blotting and immunoﬂuo-
rescence (26 DMD and 5 BMD).
Exon deletions in the dystrophin gene were detected in
37 cases (51.3%). All deletions were found clustered in the
two deletion-prone regions identiﬁed by Koenig et al [2]
(Figure 2). These ﬁndings are in agreement with other stud-
ies conﬁrming that there are no ethnic diﬀerences in the
distribution of dystrophin gene deletions [18, 19]. Among
the 37 deletions detected, 81% were found in exons 43 to
52, 16% in the promoter region to exon 12 and one patient
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Figure 2. Schematic representation of diﬀerent deletions in the dystrophin
gene as detected in Moroccan patients (horizontal lines). The top numbers
indicate the ampliﬁed exons. The arrow indicates the most frequent dele-
tion.
mutation covered both hot spots including exon 12 region
to exon 48. The most frequent deletion found in this series
(detected in 5 patients) is the one spanning the region from
exon 45 to exon 48.
The diagnosis of DMD or BMD was conﬁrmed by dys-
trophin analysis in only 31 patients, 16 of which had dys-
trophin gene deletions, that is, approximately 50%. In the re-
maining42cases,musclebiopsycouldnotbeobtainedeither
because the parents refused or because the patient was not
hospitalized.
Overall, 58 patients had a conﬁrmed dystrophinopathy,
following DNA and/or dystrophin analysis, and a family his-
tory compatible with X-linked inheritance without deletion
(in 6 cases).
Among the 72 patients, 13 cases had a family history
and 15 patients were inbred individuals, which represent
20% of cases. Taking into consideration this level of in-
breeding, another autosomal recessive muscular dystrophy,
particularly a gamma-sarcoglycanopathy, could be suspected
in the fourteen remaining cases without deletion and for
which no dystrophin analysis was done. With the exception
ofonecase,allthosecasesweresporadicbecausethegamma-
sarcoglycanopathy is also frequent in Morocco, dystrophin
analysis is still important to conﬁrm or exclude the diagnosis
of DMD/BMD particularly in sporadic cases without dele-
tion.However,detectionofdeletionsprovidesaccurateinfor-
mationforgeneticcounselling,andprenataldiagnosiscanbe
proposed tofemalecarriers.Itisinteresting tonotethatdele-
tions in Moroccan patients are most frequent in the region
from exon 43 to exon 52. For the families of DMD without
deletions, linkage analysis using polymorphic markers is still
the only possibility proposed to females at risk.
Duchenne muscular dystrophy patients are wheelchair-
bound after the ﬁrst decade. In Morocco, as in many coun-
tries,thisplacesaheavyburdenonthefamiliesoftheaﬀected
individuals as well as the country’s health care system. The160 Aziza Sbiti et al 2:3 (2002)
progress of genetic technology and the application of new
approaches for DNA analysis, such as multiplex PCR, allow a
rapid molecular diagnosis, which, in the absence of therapy,
may currently be the only approach for prevention, through
genetic counselling and prenatal diagnosis.
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